2015–16 Catalan government formation

AOP Health Starts Research for Leukemia Treatment

Retrieved on: 
Monday, August 1, 2022
Generalitat, Novartis, Biomedical Research, Degenerative disease, Sant Pau, Intention, Catalan, UAB, Spanish government departments, 2015–16 Catalan government formation, Lymphatic system, Campus, AOP, VC, Group, Investment, HTR1B, Autonomous university, Union, Catalan Institute of Nanoscience and Nanotechnology (ICN2), Research, Solution, Leukemia, Cancer, Bone marrow, Critical care, List of life sciences, Myelodysplastic syndrome, Neoplasm, GLOBE, CERCA, Illuminating Engineering Society, Disease, Science, MDS, Investor, Medicine, University, AML, Patient, Health, Pharmaceutical industry, Medical device, Nasdaq

VIENNA, Austria, Aug. 01, 2022 (GLOBE NEWSWIRE) -- The AOP Health Group (AOP Health) is a European pioneer for integrated therapies for rare diseases and in critical care headquartered in Vienna, Austria.

Key Points: 
  • VIENNA, Austria, Aug. 01, 2022 (GLOBE NEWSWIRE) -- The AOP Health Group (AOP Health) is a European pioneer for integrated therapies for rare diseases and in critical care headquartered in Vienna, Austria.
  • In early July, AOP Health signed an agreement with Leukos Biotech, a spin-off company founded by the Barcelona-based Josep Carreras Leukaemia Research Institute.
  • At first, AOP Health will focus on the development of treatment options for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).
  • The AOP Health Group incorporates several companies including AOP Orphan Pharmaceuticals GmbH with its seat in Vienna, Austria (AOP Health).

SOPHiA GENETICS Launches New Solution to Advance Chronic Lymphocytic Leukemia Care, in Collaboration with IDIBAPS

Retrieved on: 
Thursday, June 9, 2022
Institute, Platform, Chronic lymphocytic leukemia, Sophia, Technology, Research, Generalitat, U.S. Securities and Exchange Commission, Blood, SF3B1, Forward-looking statement, Partnership, Solution, Trisomy, Faculty, Acute myeloid leukemia, Lymphoma, BTK, CLL, Biomedical Research, Noise, DDM, CNV, Guideline, Algorithm, SNV calling from NGS data, University, Health, Patient, DNA, PLCG2, Sophia Genetics, University of Barcelona, Software as a service, Leukemia, NGS, GENETICS, LinkedIn, Disease, Environment, Catalan, ATM, TP53, NOTCH1, Workflow, BCL2, 2015–16 Catalan government formation, Twitter, Instagram, Medical device, Pharmaceutical industry, Genetics, Hematology, Medicine

SOPHiA GENETICS has already facilitated the analysis of one million genomic profiles through the SOPHiA DDM Platform, including a significant amount of onco-hematological-related diseases such as acute myeloid leukemia and lymphomas.

Key Points: 
  • SOPHiA GENETICS has already facilitated the analysis of one million genomic profiles through the SOPHiA DDM Platform, including a significant amount of onco-hematological-related diseases such as acute myeloid leukemia and lymphomas.
  • The new CLL solution allows for progress of Chronic Lymphocytic Leukemia research using genomic analysis.
  • "We are proud to work together with some of the most renowned experts in the field of Chronic Lymphocytic Leukemia research around the world.
  • Forward-looking statements are based on SOPHiA GENETICS' management's beliefs and assumptions and on information currently available to its management.

SOPHiA GENETICS Launches New Solution to Advance Chronic Lymphocytic Leukemia Care, in Collaboration with IDIBAPS

Retrieved on: 
Thursday, June 9, 2022
Institute, Platform, Chronic lymphocytic leukemia, Sophia, Technology, Research, Generalitat, U.S. Securities and Exchange Commission, Blood, SF3B1, Forward-looking statement, Partnership, Solution, Trisomy, Faculty, Acute myeloid leukemia, Lymphoma, BTK, CLL, Biomedical Research, Noise, DDM, CNV, Guideline, Algorithm, SNV calling from NGS data, University, Health, Patient, DNA, PLCG2, Sophia Genetics, University of Barcelona, Software as a service, Leukemia, NGS, GENETICS, LinkedIn, Disease, Environment, Catalan, ATM, TP53, NOTCH1, Workflow, BCL2, 2015–16 Catalan government formation, Twitter, Instagram, Medical device, Pharmaceutical industry, Genetics, Hematology, Medicine

SOPHiA GENETICS has already facilitated the analysis of one million genomic profiles through the SOPHiA DDM Platform, including a significant amount of onco-hematological-related diseases such as acute myeloid leukemia and lymphomas.

Key Points: 
  • SOPHiA GENETICS has already facilitated the analysis of one million genomic profiles through the SOPHiA DDM Platform, including a significant amount of onco-hematological-related diseases such as acute myeloid leukemia and lymphomas.
  • The new CLL solution allows for progress of Chronic Lymphocytic Leukemia research using genomic analysis.
  • "We are proud to work together with some of the most renowned experts in the field of Chronic Lymphocytic Leukemia research around the world.
  • Forward-looking statements are based on SOPHiA GENETICS' management's beliefs and assumptions and on information currently available to its management.

PerkinElmer’s SIRION Biotech Teams with Centre for Genomic Regulation to Develop New Generation AAV Vectors for Type 1 and Type 2 Diabetes Gene Therapy

Retrieved on: 
Wednesday, February 16, 2022
Science, Biotechnology, Research, Pharmaceutical, Health, Diabetes, Medical Devices, Genetics, Form 10-Q, Instagram, Intellectual property, European, AAV, CERCA, United, Company, Science, Government, YouTube, Catalan, LIBOR, 2015–16 Catalan government formation, Informatics, U.S. Securities and Exchange Commission, Pancreas, Security (finance), Genome, Private Securities Litigation Reform Act, Union, EMBL-EBI, Safety, Precision medicine, Decision-making, Risk, Intention, Genomics, CRG, Compliance, LinkedIn, PerkinElmer, Twitter, Diabetes, Sale, Â, Centre for Genomic Regulation, BIST, Food, Failure, Automation, Research, COVID-19, ESG, Life, Industry, Drug development, Center, Vaccine, Pharmaceutical industry, Technology, Facebook, PerkinElmer, the Centre for Genomic Regulation, PERKINELMER, THE CENTRE FOR GENOMIC REGULATION

The collaboration combines SIRIONs AAV technology platform and expertise in viral vector development and production with CRGs deep knowledge of genetic regulatory mechanisms.

Key Points: 
  • The collaboration combines SIRIONs AAV technology platform and expertise in viral vector development and production with CRGs deep knowledge of genetic regulatory mechanisms.
  • The end goal is to develop AAV vectors that target specific pancreatic cell types and contain payloads that express therapeutic genes under control of cell-specific regulatory elements.
  • This new approach aims to increase the precision, safety, and efficacy of future AAV based gene therapies for diabetes.
  • The company offers one of the worlds most comprehensive viral vector technology platforms based on lenti-, adeno-, and adeno-associated viruses to expedite gene therapy research and advance drug development.